Australia Pain Management Drugs Market Size, Share, Opportunities, And Trends By Drug Type (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Acetaminophen, Opioid (Strong Opioid, Weak Opioid), Antidepressants, Anticonvulsant Drugs, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Indication (Cancer, Rheumatoid Arthritis, Chronic Back Pain, Post-Operative Pain, Others), And By State - Forecasts From 2025 To 2030

Australia Pain Management Drugs Market Size:

Australia pain management drugs market is anticipated to grow at a CAGR of XX% from 2025 to 2030.

Pain management drugs are majorly used in treating short-term acute and chronic pain and with the growing geriatric population in Australia, the demand for such drugs is anticipated to pick up pace. According to the National Health Survey (NHS) 2022 conducted by the Australian Bureau of Statistics, nearly 22.3% of Australians aged between 65 to 74 years reported poor health, and the percentage share reached 31.3% for people aged over 75 years. Old age is more prone to chronic pain and with such constant health fluctuation, the scale of medicine consumption for pain management is anticipated to show progression.

Likewise, the prevalence rate of rheumatoid arthritis in Australia is also showing progression, for instance, according to Arthritis Australia, nearly 4.11 million Australians are suffering from arthritis, and by 2050 the figure is expected to grow to 5.39 million. The same source also stated that rheumatoid arthritis and musculoskeletal conditions constitute 12.7% of the total disease burden in Australia and 20% of the total arthritis patients require assistance in daily activity.

Besides musculoskeletal issues dealing with chronic disease prevalence inclusive of diabetes, cancer, and cardiac disease in Australia have also become a major concern for people, and with the high number of cases reported the demand for medication to suppress pain in such conditions is also expected to grow. Moreover, the level of surgical procedures in the country is growing constantly which is attributable to the growing emergency medical conditions.

According to the Australian Institute of Health and Welfare, in 2023 the number of patients admitted for elective surgery reached 778,500 which marked a 5.8% growth over the number of admissions in 2022. With such admissions, the demand for medication used post-operations will also show simultaneous growth thereby paving the way for future market expansion for pain management drugs in Australia. Additional factors like favorable government policies to bolster healthcare access followed by strategic investments by key market players to expand their operations have also provided new growth prospects.

Australia Pain Management Drug Market Segmentation

• By Drug Type
  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Acetaminophen
  • Opioid
    • Strong Opioid
    • Weak Opioid
  • Antidepressants
  • Anticonvulsant Drugs
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Indication
  • Cancer
  • Rheumatoid Arthritis
  • Chronic Back Pain
  • Post-Operative Pain
  • Others
• By State
  • New South Wales
  • Queensland
  • Victoria
  • South Australia
  • Others

1. EXECUTIVE SUMMARY 

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE 

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities 

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations 

3.7. Strategic Recommendations 

4. TECHNOLOGICAL OUTLOOK

5. AUSTRALIA PAIN MANAGEMENT DRUGS MARKET BY DRUG TYPE

5.1. Introduction

5.2. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

5.3. Corticosteroids

5.4. Acetaminophen

5.5. Opioid

5.5.1. Strong Opioid

5.5.2. Weak Opioid

5.6. Antidepressants

5.7. Anticonvulsant Drugs

5.8. Others

6. AUSTRALIA PAIN MANAGEMENT DRUGS MARKET BY DISTRIBUTION CHANNEL

6.1. Introduction

6.2. Hospital Pharmacies

6.3. Retail Pharmacies 

6.4. Online Pharmacies

7. AUSTRALIA PAIN MANAGEMENT DRUGS MARKET BY INDICATION

7.1. Introduction

7.2. Cancer

7.3. Rheumatoid Arthritis

7.4. Chronic Back Pain

7.5. Post-Operative Pain

7.6. Others

8. AUSTRALIA PAIN MANAGEMENT DRUGS MARKET BY STATES

8.1. Introduction

8.2. New South Wales

8.2.1. By Drug Type

8.2.2. By Distribution Channel

8.2.3. By Indication

8.3. Queensland

8.3.1. By Drug Type

8.3.2. By Distribution Channel

8.3.3. By Indication

8.4. Victoria

8.4.1. By Drug Type

8.4.2. By Distribution Channel

8.4.3. By Indication

8.5. South Australia

8.5.1. By Drug Type

8.5.2. By Distribution Channel

8.5.3. By Indication

8.6. Others

8.6.1. By Drug Type

8.6.2. By Distribution Channel

8.6.3. By Indication

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. Novartis Pharmaceuticals Corporation (Novartis AG)

10.2. Eli Lilly and Company

10.3. Pfizer Inc.

10.4. GlaxoSmithKline plc

10.5. Sanofi S.A

10.6. Johnson & Johnson

10.7. Viatris Inc.

10.8. Abbott Laboratories

10.9. Johnson & Johnson

11. APPENDIX

11.1. Currency 

11.2. Assumptions

11.3. Base and Forecast Years Timeline

11.4. Key benefits for the stakeholders

11.5. Research Methodology 

11.6. Abbreviations 

Novartis Pharmaceuticals Corporation (Novartis AG)

Eli Lilly and Company

Pfizer Inc.

GlaxoSmithKline plc

Sanofi S.A

Johnson & Johnson

Viatris Inc.

Abbott Laboratories

Johnson & Johnson